380895-02-3

Basic information

• Product Name: C₂₃H₁₈BrN₃O₂
• Synonyms: C₂₃H₁₈BrN₃O₂
• CAS NO: 380895-02-3
• Molecular Weight: 448.319
• Mol File: 380895-02-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₃H₁₈BrN₃O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₃H₁₈BrN₃O₂(380895-02-3)
• EPA Substance Registry System: C₂₃H₁₈BrN₃O₂(380895-02-3)

Safety Data

• Hazardous Substances Data: 380895-02-3(Hazardous Substances Data)

Upstream product

• 36640-42-3 3-(4-methoxyphenyl)-1-phenyl-1H-pyrazole-4-carboxaldehyde 
• 106-40-1 4-bromo-aniline 
• 372107-36-3 3-(4-methoxyphenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid 
• 59-88-1 phenylhydrazine hydrochloride 

Relevant articles and documents

Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents

A series of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives have been designed, synthesized and evaluated for their potential antiproliferation activity and Aurora-A kinase inhibitory activity. Among all the compounds, compound 10e possessed the most potent biological activity against HCT116 and MCF-7 cell lines with IC50 values of 0.39 ± 0.06 μM and 0.46 ± 0.04 μM, respectively, which were comparable to the positive control. Compound 10e also exhibited significant Aurora-A kinase inhibitory activity (IC50 = 0.16 ± 0.03 μM). Docking simulation was performed to position compound 10e into the active site of Aurora-A kinase, in order to get the probable binding model for further study. The results of Western-blot assay demonstrated that compound 10e possessed good Aurora-A kinase inhibitory activity against HCT116. Based on the preliminary results, it is deduced that compound 10e with potent Aurora-A kinase inhibitory activity may be a potential anticancer agent.